You are here

Article Text

Article menu
Download PDFPDF
Unusual association of diseases/symptoms
CASE REPORT
Periorbital dermatitis in patients receiving docetaxel in combination chemotherapy
  1. Mika Michelle Tabata1 and
  2. Bernice Kwong2
  1. 1 Dermatology, Stanford University School of Medicine, Stanford, California, USA
  2. 2 Dermatology, Stanford Medicine, Stanford, California, USA
  1. Correspondence to Mika Michelle Tabata, mtabata1{at}stanford.edu

Abstract

Recognition of new cutaneous side effects of combination chemotherapy can help prevent unnecessary cessation or reduction of cancer therapy. Periorbital rash has not been found with docetaxel alone, but here, we report it as a result of combination chemotherapy. A series of three patients who received docetaxel in combination with other chemotherapies developed clinically near-identical, distinctive periorbital rashes. Rashes resolved by resolving underlying docetaxel-induced epiphora in conjunction with ophthalmological consultation, topical skin-directed care, and in some cases, chemotherapy dose reduction. It is important for dermatologists and oncologists to recognise the increased severity of cutaneous reactions when docetaxel is used in combination chemotherapy.

  • dermatology
  • drug interactions
  • eye
  • skin

https://doi.org/10.1136/bcr-2019-230023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors BK provided patient care and writing and editing of manuscript. MMT helped with writing and editing of manuscript and explanation and obtaining consent from patients.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.